Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2011)
15 slides from Patrys's shareholder meeting presentation, Nov 30, 2011
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 30 November 2011 Dr. Marie Roskrow Chief Executive Officer ASX: PAB
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 3: Corporate Overview
Corporate Overview For personal use only KEY STATISTICS – 31 OCTOBER 2011 (A$) 1 YEAR SHARE PERFORMANCE ASX Code PAB $0.15 Current share price $0.057 $0.13 Share Price A$ 52 Week High $0.18 $0.11 52 Week Low $0.05 $0.09 Shares on Issue 249,213,898 $0.07 Market Capitalisation $14.2 m $0.05 Cash (30 S
Slide 4: Pipeline Progress – Past months
Pipeline Progress – Past 12 months Patrys has moved from being a preclinical to a clinical-stage oncology company For personal use only PAT-SM6 Clinical: Phase 1 single-dose melanoma study commenced August 2010 Safe in all treated patients to date Detected presence of PAT-SM6 in tumours of 2 treat
Slide 5: Capital Raising
Capital Raising For personal use only Details of the Offer Amount: $3 million (Patrys reserves the right for overs of up to $2 million) Issue Price: 3 cents per share Method: Placement to institutional and sophisticated investors 37 million shares under 15% placement capacity Balance subject to shar
Slide 6: PAT-SM6 Melanoma Trial
PAT-SM6 Melanoma Trial For personal use only Single dose, dose-escalating, trial of PAT-SM6 in N=9 patients with recurrent in- transit cutaneous melanoma Royal Adelaide Hospital and Princess Alexandra Hospital, Brisbane currently enrolling Three dose cohorts (0.15, 0.3, 0.6mg/kg), i.v. adminis
Slide 7: PAT-SM6 Melanoma Trial
PAT-SM6 Melanoma Trial Pre treatment biopsy Biopsy after PAT-SM6 treatment For personal use only Patient 1 Patient 2 Melanoma patient tumour biopsies were collected before and after treatment with PAT-SM6, fixed in formalin and embedded in paraffin. An antibody specific for PAT-SM6 (PAT-SM6 anti Idi
Slide 8: Multiple Myeloma Opportunity
Multiple Myeloma Opportunity For personal use only A cancer of the plasma cells in bone marrow. These cells grow out of control and form tumours in solid bone Estimated to be more than 200,000 cases worldwide and incidence increasing 5 year survival of approx. 40% (10yr≈20%). Despite new marke
Slide 9: PAT-SM6 Multiple Myeloma Preclinical Data
PAT-SM6 Multiple Myeloma Preclinical Data For personal use only GRP78 (PAT-SM6 target) is expressed on MM tissues PAT-SM6 binds to both MM patient bone marrow (N=20/20) and MM cell lines (N=5/5) Treatment of patient tissues and cell lines with PAT-SM6 leads to significant cell death Cell dea
Slide 10: PAT-SM6 Multiple Myeloma Preclinical Data
PAT-SM6 Multiple Myeloma Preclinical Data For personal use only Patient tissue sourced Isotype Control CD138 PAT-SM6 from 11 patients at primary diagnosis, 9 with MM1 relapsed disease and 4 healthy controls Immunohistochemical staining on bone marrow MM2 sections revealed binding of PAT-SM6 in 2
Slide 11: PAT-SM6 Multiple Myeloma Trial Design
PAT-SM6 Multiple Myeloma Trial Design For personal use only Phase I/IIa open-label multi-dose trial in relapsed and multi-resistant patients (N=10- 12 in 3-4 dosing groups) Primary endpoint=safety. Secondary endpoints include measures of efficacy University of Würzburg Phase I/II unit Commen
Slide 12: PAT-SC1 (Gastric Cancer)
PAT-SC1 (Gastric Cancer) For personal use only Pentameric IgM antibody PAT-SC1 Overview First antibody from pipeline evaluated in PAT-SC1 Binding clinical trial to CD55 CD55 Tumour Cell Target: Binds to isoform of CD55 expressed on CD55 multiple types of cancer cells Safe in 51 patients rece
Slide 13: PAT-LM1
PAT-LM1 For personal use only Pentameric IgM antibody Lung Cancer Animal Model Overview Potent killing activity across multiple cancers Binds to NONO protein expressed in 98% of over 200 different patient tumours screened Target: Third party research confirms NONO several critical roles of N
Slide 14: Plans For 2012
Plans For 2012 For personal use only Complete PAT-SM6 melanoma trial and release full data (1Q12) Finalise preclinical work to support a PAT-SM6 multiple myeloma trial Commence PAT-SM6 Phase I/IIa open label multi-dose multiple myeloma clinical trial Out-license PAT-SC1 Further prepare PAT
Slide 15: For Further Information
For Further Information For personal use only Contact Details Dr. Marie Roskrow, Chief Executive Officer Roger McPherson, Chief Financial Officer Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com 15